Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 5/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806202 | 0.84 | ERN1 (0.43) | BRD4INPPL1LRRK2CREBBPDYRK1A | |
| SCHEMBL17809771 | 0.83 | BRD4 (0.39) | BRD4RETLRRK2AXLCREBBP | |
| SCHEMBL17806302 | 0.83 | RET (0.42) | RETLRRK2 | |
| SCHEMBL17806206 | 0.76 | KDM1A (0.48) | BRD4LRRK2CREBBPDYRK1AKDM1A | |
| SCHEMBL17806217 | 0.73 | NOTUM (0.51) | BRD4LRRK2CREBBPKDM1A | |
| SCHEMBL17806268 | 0.71 | ROCK2 (0.36) | BRD4RETLRRK2CREBBP | |
| SCHEMBL17806259 | 0.71 | KDM1A (0.49) | BRD4LRRK2CREBBPDYRK1AKDM1A | |
| SCHEMBL17806357 | 0.71 | CREBBP (0.45) | BRD4CREBBP | |
| SCHEMBL17806240 | 0.70 | CREBBP (0.38) | BRD4RETCREBBP | |
| SCHEMBL17806382 | 0.69 | USP30 (0.55) | RETLRRK2CREBBPCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | BRD4 11/4885RET 855/4885INPPL1 3124/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | BRD4 11/4885RET 855/4885INPPL1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.